Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 9/20 | 0.79 |
| ▸ | ANPEP | P15144 | 5/20 | 0.79 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Iv SCHEMBL4322236 | 0.90 | LNPEP (0.68) | LNPEPANPEPNTSR2NTSR1AGTR1 | |
| Angiotensin Iv SCHEMBL4322224 | 0.90 | LNPEP (0.68) | LNPEPANPEPNTSR2NTSR1AGTR1 | |
| SCHEMBL4757569 | 0.89 | LNPEP (0.63) | LNPEPANPEPNTSR2NTSR1AGTR1 | |
| SCHEMBL4756901 | 0.87 | LNPEP (0.61) | LNPEPANPEPNTSR2NTSR1AGTR1 | |
| SCHEMBL9010597 | 0.87 | LNPEP (0.64) | LNPEPANPEPNTSR2NTSR1AGTR1 | |
| SCHEMBL9010601 | 0.87 | LNPEP (0.64) | LNPEPANPEPNTSR2NTSR1AGTR1 | |
| SCHEMBL29602804 | 0.87 | LNPEP (0.59) | LNPEPANPEPNTSR2NTSR1AGTR1 | |
| SCHEMBL4757539 | 0.86 | LNPEP (0.60) | LNPEPANPEPAGTR1AGTR2F2 | |
| SCHEMBL13081986 | 0.85 | LNPEP (0.60) | LNPEPANPEPNTSR2NTSR1AGTR1 | |
| SCHEMBL11204440 | 0.85 | LNPEP (0.60) | LNPEPANPEPNTSR2NTSR1AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115163-A1 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2012-05-10 | — | — | US | disclosed |
| WO-2010133806-A2 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP | UNIVERSITE JOSEPH FOURIER (FR) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115163-A1 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP | IAPP, ANPEP, ENPEP | LNPEP 12/4885ANPEP 2/4885NTSR2 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.